MyProstateScore 2.0 (MPS2) for Prostate Cancer Early Detection
Prostate cancer remains a leading cause of cancer-related mortality in men. Conventional serum PSA testing, while prostate-specific, often leads to unnecessary invasive biopsies due to its limited specificity.
MyProstateScore 2.0 (MPS2) is a urine-based molecular test developed by University of Michigan researchers, offered by LynxDx, that estimates the risk of clinically significant prostate cancer (Grade Group ≥2; Gleason score ≥7). It detects the TMPRSS2:ERG (T2:ERG) gene fusion, a hallmark in prostate cancer, along with 17 additional genetic biomarkers.
The test uses quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to assess gene expression from urine samples collected either with or without digital rectal examination (DRE).
MPS2 provides a risk score predicting the likelihood of detecting clinically significant prostate cancer. It offers a negative predictive value (NPV) up to 99%, enabling many men to avoid unnecessary biopsies.
Samples are stable at room temperature, allowing collection in both clinical and home settings.
- Serves as triage for prostate biopsy in for both previous negative biopsy and biopsy naïve patients
- Assisting in biopsy decision-making, particularly in men with elevated PSA or abnormal DRE findings
Negative: Below established cutoff threshold (indicating low risk)
Post-DRE (Digital Rectal Examination) urine, 10 mL collected in sterile screw-capped container.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- J Urol. 2021 Mar;205(3):732-739. [PMID: 33080150]
- Prostate Cancer Prostatic Dis. 2023 Sep;26(3):563-567. [PMID: 36585434]
- Eur Urol. 2016 Jul;70(1):45-53. [PMID: 25985884]
- JAMA Oncol. 2024 Jun 1;10(6):726-736. [PMID: 38635241]
- LynxDx MyProstateScore 2.0 Provider Information